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Targeted Depletion of Polo-Like Kinase (Plk) 1
Through Lentiviral shRNA or a Small-Molecule
Inhibitor Causes Mitotic Catastrophe and Induction
of Apoptosis in Human Melanoma Cells
Travis L. Schmit1,2, Weixiong Zhong3,4, Vijayasaradhi Setaluri1,2,4, Vladimir S. Spiegelman1,2,4 and
Nihal Ahmad1,2,4
Melanoma, one of the most lethal forms of skin cancer, remains resistant to currently available treatments.
Therefore, additional target-based approaches are needed for the management of this neoplasm. Polo-like
kinase 1 (Plk1) has been shown to be a crucial regulator of mitotic entry, progression, and exit. Elevated Plk1
level has been associated with aggressiveness of several cancer types and with poor disease prognosis.
However, the role of Plk1 in melanoma is not well established. Here, we show that Plk1 is overexpressed in both
clinical tissue specimens and cultured human melanoma cells (WM115, A375, and HS294T) when compared with
normal skin tissues and cultured normal melanocytes, respectively. Furthermore, Plk1 gene knockdown through
Plk1-specific shRNA or its activity inhibition by a small-molecule inhibitor resulted in a significant decrease in
the viability and growth of melanoma cells without affecting normal human melanocytes. In addition, Plk1
inhibition resulted in a significant (i) decrease in clonogenic survival, (ii) multiple mitotic errors, (iii) G2/M cell-
cycle arrest, and (iv) apoptosis of melanoma cells. This study suggests that Plk1 may have a functional relevance
toward melanoma development and/or progression. We suggest that the targeting of Plk1 may be a viable
approach for the treatment of melanoma.
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INTRODUCTION
Melanoma is one of the most aggressive, metastatic and lethal
forms of skin cancer that has frustrated both clinicians and
researchers for several decades. The incidence of melanoma
has been increasing at an alarming rate; it is estimated that
B62,000 new cases of melanoma will have been diagnosed
with over 8,000 expected deaths because of the disease in the
year 2008 (Jemal et al., 2008). A recent analysis of the SEER
(Surveillance, Epidemiology, and End Results) program data
has suggested that the age-adjusted annual incidence of both
young men and women has alarmingly increased over the
past 20 years (Purdue et al., 2008). Most of the available
therapeutic regimens have not been able to achieve greater
than 25% response (Hocker et al., 2008). Similarly, the
prevailing preventive approaches have not been successful in
curtailing the growing incidence of this neoplasm. Given the
rising incidence of melanoma and the paucity of effective
treatments, additional target-based approaches are needed to
control this neoplasm.
An orchestrated control of cell cycle, including mitotic
cell division, is essential and an error-free chromosomal
segregation during cell division is of utmost importance for
the maintenance of correct ploidy and genomic integrity;
errors in cell division may result in aneuploidy and cancer
(Rajagopalan and Lengauer, 2004; Santamaria et al., 2007;
Schmit and Ahmad, 2007). For proper cell division, the
daughter cells must receive the correct complement of
chromosomes for which two critical events are required:
(1) the chromosomes need to be equally segregated with
the help of the mitotic spindle and (2) cytokinesis (the
process dividing the cell into two) must occur without error
(Rajagopalan and Lengauer, 2004; Santamaria et al., 2007;
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Schmit and Ahmad, 2007). Both of these processes are
controlled in part by a critical cell-cycle regulator, Polo-like
kinase 1 (Plk1), a member of a family of conserved serine/
threonine protein kinases. The founding member of all Plks,
polo, was originally discovered in Drosophila melanogaster
(Llamazares et al., 1991). Since its discovery, conserved polo
homologs have been defined across a variety of species,
including mammals, yeast, zebrafish, Xenopus laevis, and
Caenorhabditis elegans (Takai et al., 2005). Of the four
mammalian Plks (Plk 1–4), Plk1 is the most widely studied
member of the family. Plk1 gene expression is tightly
controlled with mRNA accumulation beginning in the S
phase with peak levels detected at the G2/M transition and
through mitosis with a corresponding increase in protein
levels and kinase activity paralleling the increase in mRNA
(Lee et al., 1995). Plk1 contributes to multiple processes at
both the G2/M transition and throughout mitosis, including
activation of the Cdk1/cyclin B1 cascade, centrosome
maturation, bipolar spindle formation, the regulation of
Emi1 degradation at mitotic exit, and cytokinesis (Ohkura
et al., 1995; Lane and Nigg, 1996; Descombes and Nigg,
1998; Roshak et al., 2000; Toyoshima-Morimoto et al., 2001,
2002; Eckerdt and Strebhardt, 2006; Burkard et al., 2007).
Plk1 is also able to destabilize and reduce p53 activity
through direct binding and phosphorylation of p53 (Ando
et al., 2004).
In mammalian cells, a dysregulation of Plk1 has been
shown to result in the formation of abnormal centrosomes,
leading to increased chromosomal instability, aneuploidy,
and tumor development (Simizu and Osada, 2000). Further-
more, forced overexpression of Plk1 in normal cells has been
found to cause a transformed phenotype and increased
tumorigenicity, suggesting that Plk1 acts as an oncogene
(Smith et al., 1997). In addition, both the genetic and
chemical inhibition of Plk1 expression levels and activity
have been shown to result in a decrease in cell growth in
certain cancer cells (Spankuch-Schmitt et al., 2002; Reagan-
Shaw and Ahmad, 2005; Strebhardt and Ullrich, 2006;
Lansing et al., 2007). Interestingly, Liu and Erikson have
shown that Plk1 depletion did not impart antiproliferative
effects in normal cells with a higher proliferative index
(hTERT-RPE1 and MCF10A) and the cells continued to
proliferate at a similar rate when compared with control for
up to 2 weeks (Liu et al., 2006). The authors found that unless
p53 expression was concomitantly knocked down with Plk1,
these normal cells, even with 490% Plk1 elimination, did
not show obvious changes in mitotic phenotypes or
proliferative indices (Liu et al., 2006).
Studies have shown that Plk1 (i) is overexpressed in several
human cancers, (ii) could serve as a marker for cancer
progression, and (iii) is strongly associated with a poor
prognosis in some types of cancer. (Strebhardt et al., 2000;
Kneisel et al., 2002; Yamada et al., 2004; Weichert et al.,
2004a, b, 2005b; Eckerdt et al., 2005; Reagan-Shaw and
Ahmad, 2005; Takai et al., 2005). Interestingly, Plk1
expression has been shown to be independent of the
proliferation marker Ki-67 expression (Takai et al., 2001a, b;
Ito et al., 2004; Mito et al., 2005; Weichert et al., 2005a).
On the above bases, the essential role in mitosis, and the fact
that it possesses two possible targeting sites (the catalytic
kinase domain and the conserved polo box domains), Plk1 is
being increasingly appreciated as an attractive target for the
management of certain cancers (Eckerdt et al., 2005; Reagan-
Shaw and Ahmad, 2005; Takai et al., 2005; Strebhardt and
Ullrich, 2006; Schmit and Ahmad, 2007).
The functional role of Plk1 in melanoma is not well
understood. Two reports have suggested that Plk1 may
have prognostic significance in patients with melanoma
(Strebhardt et al., 2000; Kneisel et al., 2002). These reports
lay stress on the need for detailed in-depth studies to
determine whether (i) Plk1 has any functional significance
in melanoma and whether (ii) Plk1 could be exploited as a
target for the development of drugs or preventive approaches
toward the management of this fatal disease. This study was
designed to determine the functional significance of Plk1 in
melanoma. To our knowledge, this is the first study to show
that Plk1 has a critical role in melanoma cell survival and
could serve as a target for the development of new
approaches to combat this disease.
RESULTS
Plk1 is overexpressed in human melanoma tissues compared
with normal skin
As a first step in our study, using a human tissue microarray
containing 40 normal and 37 malignant melanoma samples
(both matched adjacent and unmatched samples), we
determined the expression pattern of Plk1 in clinical human
melanoma samples. The tissue microarray consisted of tumor
samples arising not only from the skin but also from the oral
cavity, esophagus, rectum, and cunnus. They represented a
range of grades using the tumor-node-metastasis (TNM)
grading system. There was an even range of invasiveness
(T2–T4) and very few samples showing metastasis, with one
sample showing metastasis in four or more lymph nodes (N2)
and none with distant metastasis (M0). We found that
melanoma samples showed strong immunostaining of Plk1
compared with normal epidermal cells; the representative
images of both normal and malignant melanoma of different
scores are shown in Figure 1a. Positive Plk1 cores showed a
homogeneous, granular, cytoplasmic staining. Of the 40
individual normal cores, the epidermis of 38 (95%) cases
showed negative or weak staining, with only 2 (5%) cores
scored as moderate, and none scored as strong (Figure 1b).
Having a low yet detectable level of Plk1 (weak) in normal
skin tissue is not surprising as the skin is constantly turning
over. Conversely, of the 37 malignant melanoma cores, 5
(13.5%) cases scored as negative, 10 (27%) cases scored as
weak, and 22 (60%) cases were scored as moderate or strong
staining for Plk1. Statistically, when the tissue types (normal
or melanoma) were grouped and categorized as either
negative or weak versus moderate or strong staining, we
found that Plk1 is significantly overexpressed in melanoma
(Figure 1c).
Specificity of the anti-Plk1 antibody (Ab) used was
confirmed by both immunohistochemical and immunoblot
analyses. We tested the ability of recombinant Plk1 to
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eliminate positive Plk1 bands of both endogenous and
overexpressed Plk1 through immunoblot analysis (Supple-
mentary Figure 1A). Furthermore, all cores showed negative
staining when control IgG2b sera were used (Supplementary
Figure 1B). Staining of Plk1 was sample specific and not
attributable to nonspecific background staining as shown by
negative staining of the stroma in both normal and tumor
cores (Figure 1 and Supplementary Figure 1C). Finally,
positive Plk1 staining was not necessarily a melanocyte-
specific occurrence as shown by the negative staining of
melanin-containing cells within normal skin samples
(Supplementary Figure 1D).
Plk1 is overexpressed in melanoma cells and is required for
their growth
To understand the role of Plk1 in melanoma, we determined
its expression profile in three melanoma cell lines (the
primary, vertical-growth, non-tumorigenic cell line WM115;
the primary, vertical-growth, tumorigenic cell line A375; and
the tumorigenic, metastatic cell line HS294T) compared with
primary, normal human epidermal melanocytes (NHEMs).
Our data showed that, compared with the NHEMs, Plk1
mRNA as well as protein is significantly overexpressed in
melanoma cells, although at different levels in different
melanoma cell lines (Figure 2a). Using quantitative real-time
reverse transcriptase PCR (RT-PCR), we found Plk1 mRNA
expressed in melanoma cells at 5- to 20-fold higher than in
NHEMs. A similar pattern was observed at the protein level
with Plk1 protein showing a 20- to 40-fold increase in
melanoma cells compared with the NHEMs.
Next, we determined the effects of Plk1 inhibition on the
viability and growth of melanoma cells. As shown in Figure
2b, the genetic knockdown of Plk1 through lentiviral shRNA-
mediated RNA interference and chemical activity inhibition
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Figure 1. Plk1 is overexpressed in human melanoma tissues compared with normal skin tissue samples. (a) Immunohistochemical staining of Plk1. A tissue
microarray was stained for Plk1; a Vector Red (Vector Labs) substrate was used, resulting in a pink to strong red color for positive Plk1 staining. Representative
cores for both normal and melanoma samples are shown. Original magnification of large panels are 10 and inset windows are 60. (b) Quantitation
of Plk1 immunostaining. Cores were blindly and semiquantitatively scored for Plk1 staining intensity as negative (0), weak (1þ ), moderate (2þ ), or strong (3þ ).
Tissue types were grouped into either negative or weak staining compared with moderate or strong for statistical analysis. Numbers represent the total number
of cores in each scoring intensity group. Numbers in parentheses are the percentage of cores within each tissue type (normal or melanoma) in each of the
four scoring categories. The groups were compared using a two-tailed Fisher’s exact test with a P-value of 1.99 107 and therefore considered statistically
significant. (c) Mean Plk1 score intensity. The mean staining score for each tissue type is shown at ±99% confidence interval.
www.jidonline.org 2845
TL Schmit et al.
Plk1 in Melanoma
(through GW843682X (5-(5,6-dimethoxy-1H-benzimidazol-
1-yl)-3-([2-(trifluoromethyl)-benzyl]oxy) thiophene-2-carbox-
amide)) of Plk1 resulted in a significant decrease in the Plk1
protein levels and kinase activity, respectively (Figure 2b).
GW843682X treatments had no effect on Plk1 protein levels
(Supplementary Figure 2A). As measured by trypan blue
exclusion analysis, knockdown of Plk1 gene caused a
significant reduction in the viability and growth of all the
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Figure 2. Plk1 is overexpressed in melanoma cells compared with normal melanocytes, and Plk1 inhibition causes a decrease in the viability and growth
melanoma cells. (a) Plk1 mRNA and protein levels in melanoma cells versus normal human epidermal melanocytes (NHEMs). Quantitative real-time RT-PCR
(left panel) and western blot analysis (right panel) of endogenous Plk1 expression were performed using NHEMs and three melanoma cell lines WM115, A375,
and HS294T. For RT-PCR, Plk1 mRNA levels were quantitated relative to GAPDH mRNA and calculated using the DDCT method. The protein levels were
quantitated by a densitometric analysis of protein bands. The data (relative density normalized to b-actin) are expressed as the mean±SD of three experiments
(*Po0.01). (b) Plk1 inhibition by shRNA and GW843682X. Plk1 protein levels (left panel) and kinase activity (right panel) were evaluated after lentiviral
transduction through Plk1 shRNA (72 hours) or GW843682X (24 hours) treatments, respectively. Western blot analysis was performed to assess the knockdown
of Plk1. Plk1 protein levels were quantitated by a densitometric analysis of protein bands. The data (relative density normalized to b-actin) are expressed as the
mean±SD of three experiments (*Po0.01). Kinase activity was measured to assess the inhibition of Plk1 activity. Plk1 was immunoprecipitated from lysates of
cells exposed to GW843682X and its ability to phosphorylate casein was evaluated. Phosphorylated casein levels were quantitated and expressed as mean
casein phosphorylation relative to the Plk1 protein present in the 10% aliquot of the immunoprecipitation and then normalized to control±SD of three
experiments (*Po0.01). (c and d) Effect of Plk1 inhibition on viability and growth of melanoma cells versus NHEMs. After Plk1 shRNA transduction (c) or
treatment with GW843682X (d), WM115, A375, HS294T, and NHEM cells were counted using Trypan blue analysis (white¼ viable, blue¼ non-viable). Cell
viability (left panels) was quantitated as the percent viable of total cells counted. Cell growth was determined by counting the total number of cells and
quantitated by normalizing each treatment to their respective controls. The data represent the mean±SD of three experiments with similar results (*Po0.01).
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melanoma cells tested (Figure 2c). However, the shPlk1
transduction did not have any effect on the viability or growth
of the NHEMs (Figure 2c). Although Plk1 knockdown caused
a modest (B25%) reduction in the viability of all the
melanoma cells, we found a more robust reduction in cell
growth (B40% in WM115 and HS294T; B60% in A375).
Similarly, chemical inhibition using GW843682X caused a
significant dose-dependent decrease in the viability and
growth of melanoma cells without any effect on the NHEMs
(Figure 2d). The lack of a discernible effect on the NHEMs is
similar to that observed by Liu et al. (2006), in which unless
complete abrogation of Plk1 expression is achieved with
Plk1-null knockout cells, normal, non-transformed cells
continue to proliferate without any noticeable mitotic
abnormalities or changes in proliferative indices. This is not
because of a lack of proliferation by the primary NHEMs used
in this study, as a dividing population of primary cells was
used (Supplementary Figure 2B).
We also evaluated the effects of Plk1 inhibition on cell
proliferation using an MTT (3-[4, 5-dimethylthiazol-2-yl]-2,
5-diphenyl tetrazoliumbromide) assay. As shown in
Figure 3a, we found that the genetic knockdown and
chemical inhibition of Plk1 caused a significant decrease in
proliferation of all melanoma cell lines tested. Finally, we
evaluated the effects of Plk1 inhibition on the colony
formation ability of melanoma cells. Our data showed that
both genetic knockdown and chemical inhibition resulted in
a drastic reduction in the clonogenic survival of melanoma
cells (Figure 3b and Supplementary Figure 3). Plk1 shRNA
and the higher concentrations of GW843682X (X15 mM)
resulted in almost a complete abatement (490% reduction)
in colony formation in melanoma cells.
Inhibition of Plk1 causes a G2/M cell-cycle arrest consistent
with an increase in cyclin B1 in melanoma cells
Next, we conducted experiments to determine whether or not
the antiproliferative effects of Plk1 inhibition in melanoma
cells are mediated through cell-cycle inhibition. Cell-cycle
analysis showed that both the genetic and chemical inhibi-
tion of Plk1 caused a significant increase in the cell
population in the G2/M phase of the cell cycle (Figure 4a).
Plk1 knockdown caused a significant accumulation of
melanoma cells in the G2/M phase (25, 6, and 9% in non-
sense treated compared with 43, 40, and 51% in WM115-,
A375-, and HS294T shPlk1-treated cells, respectively).
Similar results were obtained with GW843682X-mediated
inhibition of Plk1; a significant increase in G2/M cells was
observed in all three melanoma cells at the lowest
concentration of GW843682X (5 and 10 mM in WM115) after
24 hours, showing a maximum response at 20 mM concentra-
tion of GW843682X. Interestingly, the cells accumulated in
the G2/M phase were found to be a result of a shift of cell
population from the G1 phase.
Because (i) cyclin B1 shows a similar cell-cycle pattern to
Plk1, rising in the S-phase and peaking at the G2/M transition
(Soni et al., 2008), (ii) cyclin B1 is an established downstream
target of Plk1 at the G2/M transition, and (iii) an observed
increase in cyclin B1 protein level is used as a marker of
increased mitotic cells (Liu and Erikson, 2002; McNeely
et al., 2008; Soni et al., 2008), we next assessed the effect of
Plk1 inhibition on cyclin B1 protein levels through immuno-
blot analysis. We found that Plk1 inhibition (genetic as well
as chemical) resulted in an increase in cyclin B1 protein
levels, reinforcing the G2/M cell-cycle arrest (Figure 4b).
Inhibition of Plk1 causes mitotic abnormalities in melanoma
cells
Because Plk1 has been shown to control several critical
processes during mitosis, we next assessed the effect of Plk1
inhibition, through Plk1 shRNA or GW843682X (10 mM), on
mitotic errors in melanoma cells. Using immunofluorescence
to visualize a-tubulin and DNA, we carefully checked the
cells for any errors in spindle pole formation and DNA
condensation and separation after Plk1 inhibition. Our data
(Figure 4c) showed that the inhibition of Plk1 resulted in a
drastic increase in the total number of mitotic errors (B3% in
controls compared with B90% in cells treated with Plk1
shRNA or 10 mM of GW843682X). The most common
phenotype seen in mitotic cells after Plk1 inhibition was the
‘‘polo’’ phenotype (Figure 4d, A375 cells shown in the top
three rows; representative images of WM115 and HS294T
shown in Supplementary Figure 4). Earlier studies have
reported similar phenotypes (Llamazares et al., 1991; Sumara
et al., 2004; Peters et al., 2006; Lenart et al., 2007). As shown
in the bottom row of Figure 4d, the other types of mitotic
errors observed were unbalanced tubulin size (I), multi-polar
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Figure 3. Plk1 inhibition causes a decrease in melanoma cell proliferation
and colony formation. (a) Effect of Plk1 inhibition on cell proliferation—MTT
analysis. After lentiviral transduction through Plk1 shRNA (left panel) or
GW843682X treatments (right panel), MTT analysis was performed, and OD
(540–690nm) was determined to assess the effect of Plk1 inhibition on
melanoma cell growth. The data are expressed as percent proliferation and
normalized to control, mean±SD of three experiments with similar results
(*Po0.001). (b) Effect of Plk1 inhibition on colony formation. After lentiviral
transduction through Plk1 shRNA (left panel), melanoma cells were allowed
to grow for 2 weeks with media changes every 3 days with no further
selection or treatment. For GW843682X treatment (right panel), cells were
plated at 2.5 103, treated 24hours later, and re-treated every 3 days for
2 weeks. Colonies were stained with crystal violet, counted, and the data
were shown as percent colony formation (normalized to control). The data
represent the mean±SD of three experiments with similar results (*Po0.001).
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formation (II), improper tubulin alignment (III), and incorrect
cytokinesis (IV). This high percentage of cells arrested with
irreparable mitotic errors might contribute to the significant
decrease in cell growth seen with Plk1 inhibition.
Inhibition of Plk1 results in an increase in apoptosis
Because Plk1 inhibition could result in an apoptotic
elimination of cells (Fink et al., 2007; Lansing et al., 2007;
Steegmaier et al., 2007; Bu et al., 2008), we next evaluated
the effects of Plk1 inhibition on apoptosis induction in
melanoma cells. As shown by a flow cytometric evaluation of
Annexin V staining, we found that Plk1 inhibition through
shRNA-mediated knockdown or by GW843682X resulted
in a significant increase in apoptosis in melanoma cells
(Figure 5a). The effect of Plk1 inhibition on apoptosis was
also confirmed using western blot analysis for cleaved PARP
HS294T
A375
WM115
GW
84
36
82
X
DM
SOshN
S
sh
Plk
1
100
75
50
25M
ito
tic
 e
rro
rs
(%
 of
 to
tal
 ce
lls
 in
 m
ito
sis
)
IVIIIIII
M
er
ge
Tu
bu
lin
DA
PI
DMSO
WM115
A375
HS294T
DM
SO 5 μ
M
10
 μM
15
 μM
20
 μM
GW843682X shNS shPlk1
G2/MSG1G2/MSG1
G2/MSG1 G2/MSG1
G2/MSG1
G2/MSG1
75
DMSO
50
25
0P
e
rc
e
n
t o
f c
el
l
po
pu
la
tio
n
75
50
25
0P
e
rc
e
n
t o
f c
el
l
po
pu
la
tio
n
75
50
25
0P
e
rc
e
n
t o
f c
el
l
po
pu
la
tio
n
75
50
25
0P
e
rc
e
n
t o
f c
el
l
po
pu
la
tio
n
75
50
25
0P
e
rc
e
n
t o
f c
el
l
po
pu
la
tio
n
75
50
25
0P
e
rc
e
n
t o
f c
el
l
po
pu
la
tio
n
***** *
*
**
*
*
*
*
*
20 μM15 μM10 μM5 μMDMSO 20 μM15 μM10 μM5 μMDMSO 20 μM15 μM10 μM5 μM
HS294T
HS294T
A375
A375
WM115
WM115a
b
c
d
shPlk1shNSshPlk1shNSshPlk1shNS
β-Actin
β-Actin
β-Actin
sh
NS
sh
Plk
1
Cyclin B1
Cyclin B1
Cyclin B1
Figure 4. Plk1 inhibition causes a G2/M cell-cycle arrest, increase in cyclin B1, and multiple mitotic errors in melanoma cells. (a) Effect of Plk1 inhibition on
cell-cycle distribution. After lentiviral transduction through Plk1 shRNA (top panels) or GW843682X treatments (bottom panels), cells were collected and fixed
for cell-cycle distribution analysis using FACS. The quantitation of cell-cycle distribution was performed using ModFit LT software (Verity Software House,
Topsham, ME). The data represent the mean±SD of three experiments (*Po0.01). (b) Effect of Plk1 inhibition on cyclin B1. After lentiviral transduction or
GW843682X treatment, cell lysates were collected and evaluated for cyclin B1 protein levels by western blot analysis; b-actin was used as a loading control.
(c and d) Effect of Plk1 inhibition on mitotic errors—immunofluorescence. After lentiviral transduction through Plk1 shRNA or GW843682X treatments,
A375 cells were fixed, stained for a-tubulin (red), and DNA counterstained with DAPI (blue). A total of 100 mitotic cells per treatment were counted as normal
or with mitotic errors. Mitotic errors were quantitated and expressed as total mitotic errors as a percentage of total mitotic cells counted and displayed in
panel c. The various errors are shown in panel d. These errors include polo- or mono-polar cells (shown in the upper panel), improper tubulin size (I),
multi-polar (II), improper tubulin alignment (III), and improper cytokinesis (IV); representative examples are shown here. Bar¼10 mm.
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(poly[ADP-ribose] polymerase). Our data showed that Plk1
inhibition resulted in a significant increase in PARP cleavage
in melanoma cells, further supporting the increase in
apoptosis seen with Annexin V and propidium iodide (PI)
staining (Figure 5b).
DISCUSSION
Plk1 expression has been correlated with poor prognosis in
melanoma samples. Two previous studies have shown
increased Plk1 expression in clinical melanoma samples.
The first study by Strebhardt et al. (2000) found a significant
increase in Plk1 expression in a large variety of melanoma
samples, which also correlated with tumor thickness. They
also found a decrease in 10-year survival in patients with
higher Plk1 expression (Strebhardt et al., 2000). In the second
study, the authors correlated increased Plk1 expression in
thin melanomas with an increased risk of metastasis within
5 years (Kneisel et al., 2002). Our tissue microarray analysis
showed that indeed Plk1 is markedly overexpressed in
melanoma tissue compared with that in normal skin.
However, we did not attempt to correlate Plk1 expression
with tumor grade or disease outcome because of minimal
information available for a commercially available tissue
microarray. Finally, we acknowledge that co-staining for Plk1
and a melanocyte-specific marker such as Mart-1 or Mitf
would be the optimal control for normal skin tissue; however,
we show that Plk1 does not necessarily show a melanocyte-
specific staining pattern (Supplementary Figure 1). Further-
more, the normal cores showing positive Plk1 staining were
mostly undetectable to low and, based on visual inspection,
the majority of positive staining within the positive cores was
within the keratinocytes.
Plk1, a key regulator of cell division in eukaryotic cells,
has been shown to have critical roles in ensuring a smooth
and error-free progression through mitosis. Plk1 has also been
shown to have an important role in maintaining genomic
stability during DNA replication and the DNA damage
checkpoint. Plk1 functions have been shown to extend past
the ‘core’ cell cycle and it is being appreciated that the term
‘‘mitotic kinase’’ might not do justice to Plk1 (Takaki et al.,
2008). Overexpression of human Plk1 has been found in a
variety of cancers; however, the role of Plk1 in melanoma
and its functional significance is not well understood. Here,
we have shown that, compared with NHEM, Plk1 was
significantly overexpressed in all three melanoma cell lines.
Furthermore, our data have also shown that a genetic
knockdown of Plk1 or its chemical inhibition of kinase
activity through a small-molecule inhibitor resulted in a
significant reduction in viability, growth, and clonogenic
survival of melanoma cells. Interestingly, the NHEM cells
were not affected by Plk1 inhibition. This is in line with the
findings by Liu et al. (2006) showing a requirement for
complete Plk1-null knockdown or concomitant Plk1 and p53
inhibition for a reduction in cell proliferation of non-
transformed hTERT-RPE1 and MCF10A cells. This indicates
that normal cells require less Plk1 activity for proper cell-
cycle progression and reinforces the idea of ‘‘oncogene
addiction’’ in cancer cells.
In our experimental strategy, we used GW843682X,
which is a small-molecule inhibitor of Plk1 (Lansing et al.,
2007). In addition, we also used Plk1 shRNA-mediated RNA
interference approach (to knock down Plk1 gene expression)
to address any concern regarding the specificity of
GW843682X. Several published studies have used similar
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Figure 5. Plk1 inhibition causes apoptosis of melanoma cells. (a) Effect of Plk1 inhibition on Annexin V binding. After lentiviral transduction through Plk1
shRNA or GW843682X treatments, cells were collected and stained with anti-Annexin V antibody and propidium iodide (PI), and analyzed using FACS analysis.
Cells were gated and counted as viable (Annexin-negative/PI-negative), early apoptotic (Annexin-positive/PI-negative), late apoptotic (Annexin-positive/
PI-positive), or necrotic (Annexin-negative/PI-positive). Graphs represent the percentage of apoptotic cells (early þ late) of the total cell population.
The data represent the mean±SD of three experiments with similar results (*Po0.01). (b and c) Effect of Plk1 inhibition on cleavage of PARP. After
lentiviral transduction through Plk1 shRNA or GW843682X treatments, cell lysates were prepared and western blot analysis was used to evaluate PARP
cleavage using an antibody that detects cleaved PARP. Cleaved PARP levels were quantitated by a densitometric analysis of protein bands. The data
(relative density normalized to b-actin) are expressed as the mean±SD of three experiments (*Po0.001).
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Plk1 inhibitory approaches both in vitro and in vivo
(Strebhardt and Ullrich, 2006; Kawata et al., 2008; Mross
et al., 2008; Perez de Castro et al., 2008; Yu et al., 2008). The
reduction in viability and growth of melanoma cells was
accompanied by a strong and persistent G2/M phase cell-
cycle arrest. We also observed an increase in cyclin B1
protein levels, a downstream target of Plk1 and a marker for
mitosis, in melanoma cells after both chemical and genetic
inhibition of Plk1, reinforcing mitotic arrest. Furthermore,
Plk1 inhibition resulted in ‘‘mitotic catastrophe’’ with several
types of mitotic errors, with the majority of them displaying
the ‘‘polo’’ phenotype. Without functional Plk1, cells do not
properly assemble a bipolar spindle apparatus and instead
arrange the chromosomes in a circular pattern around a
monopolar spindle. However, bipolar spindle formation is
not the only function Plk1 has through mitosis. We also found
a significant increase in the number of cells with errors in
cytokinesis, which may be attributed to some of Plk1’s other
roles, such as its direct and indirect regulation of the
anaphase-promoting complex (APC/C) and its inhibitor,
Emi1; Plk1’s role in cohesin dissociation from the chromo-
some arms; or Plk1’s regulation of Ect2 and RhoA GTPase for
proper cytokinesis (Burkard et al., 2007; Schmit and Ahmad,
2007). Overall, these mitotic phenotypes by Plk1 inhibition
explain the strong mitotic arrest followed by the observed
apoptotic elimination of melanoma cells.
We observed different extents of response in different
melanoma cell lines through Plk1 inhibition. Some of the
differences, such as those seen with cell-cycle arrest and
apoptosis, may be attributable to cell line differences.
WM115 possesses non-invasive properties and is therefore
considered a less-aggressive cancer cell line, whereas A375
is a more proliferative, aggressive, and invasive tumor cell
line. This is of particular interest because A375 cells express
Plk1 at a higher level than WM115 cells, contributing to the
idea that Plk1 expression could be a good marker for poor
prognosis. It is also important to note here that the cell line
most sensitive to Plk1 knockdown (A375) with regard to
overall cell growth was the cell line that expressed Plk1 at the
highest level. This is an interesting observation in line with
the idea that tumor cells may form an ‘‘oncogene addiction’’
to various proteins or pathways for continued survival
(Weinstein, 2002). Though they may not have been the
cause of tumor formation, the increased growth of tumor cells
lends themselves to increased expression of various pathways
to continue proliferating. Therefore, although the pathway’s
continual activity or presence may not have been essential in
a non-transformed cell, even the slightest inhibition causes a
massive reduction in growth, in spite of the post-treatment
activity or expression being higher than the normal baseline.
In conclusion, our findings indicate that Plk1 is over-
expressed in both clinical melanoma samples and melanoma
cell lines. Furthermore, we showed that targeting Plk1, both
by genetic means and through a small-molecule activity
inhibitor, imparts strong antiproliferative effects, especially
‘‘mitotic catastrophe’’ followed by apoptotic elimination of
melanoma cells. This study suggests that Plk1 may have a
functional relevance toward melanoma development and/or
progression. We suggest that targeting of Plk1 for melanoma
therapy may be a viable approach for the management of
melanoma. However, further mechanism-based studies in
appropriate in vivo models are needed to validate our
findings.
MATERIALS AND METHODS
Immunohistochemistry
Paraffin-embedded human melanoma and normal skin tissue arrays
were obtained from Biomax USA (Rockville, MD). The tissue arrays
were deparaffinized with xylene and ethanol series, and antigen
retrieval was performed by heating in 1mM EDTA (pH 8.0) at 85 1C.
Slides were blocked in 10% normal goat serum (Caltag, Burlingame,
CA) in phosphate-buffered saline (PBS) for 1 hour at room
temperature, followed by incubation with anti-Plk1 Ab (Upstate,
Billerica, MA) or IgG2b control anti-sera (Upstate) diluted 1:100 in
10% normal goat serum in PBS overnight at 4 1C in a humidified
chamber. The next day, the slides were incubated with an anti-
biotin-conjugated secondary Ab (Invitrogen, Carlsbad, CA) (1:100 in
a blocking buffer) and then with a fresh ABC-Alkaline Phosphatase
reagent (Vector Labs, Burlingame, CA) for 1 hour each at room
temperature in a humidified chamber. Tissues were washed with
PBS and then exposed to fresh Vector Red reagent (Vector Labs) for
20minutes. The tissues were then counterstained with hema-
toxylin, dehydrated with ethanol and xylene, and mounted. Cores
were scored blindly for staining intensity as negative (0), weak (1þ ),
moderate (2þ ), or strong (3þ ) using the Olympus BX41 bright field
microscope (Olympus, Center Valley, PA) and images were obtained
using a digital camera (model 14.2 color Mosaic, Diagnostic
Instruments, Sterling Heights, MI) and Spot software (Windows
version 4, Diagnostic Instruments).
Cell culture
Human melanoma cell lines, WM115, A375, and HS294T (ATCC,
Manassas, VA), were maintained in Eagle’s minimum essential
medium (ATCC) or DMEM (Invitrogen) with 10% fetal bovine serum
and 1% penicillin/streptomycin at standard cell culture conditions
(37 1C in 5% CO2 in a humidified incubator). Normal human
melanocytes were isolated from neonatal foreskin and cultured as
described previously (Fang et al., 2001).
Immunoblot analysis
After treatments, cells were trypsinized, washed with ice-cold PBS,
and lysed with RIPA buffer (50mM Tris, 150mM NaCl, 1% NP-40,
0.5%. deoxycholic acid, 0.1% SDS), phenylmethylsulfonyl fluoride,
and a protease inhibitor cocktail (Pierce, Rockford, IL). Protein
concentration was measured using the BCA Protein Assay (Pierce).
For immunoblot analysis, 30 mg of protein was subjected to SDS-
PAGE using 10% Tris-HCl gels and transferred onto the nitrocellu-
lose membrane. Blots were blocked with 5% nonfat dry milk
followed by probing with the desired primary Abs (Plk1, Upstate;
cleaved PARP or cyclin B1, Cell Signaling, MA), and then
appropriate anti-HRP-conjugated secondary Abs followed by en-
hanced chemiluminescent detection. For specificity of anti-Plk1 Ab
immunoblots (Supplementary Figure 1), anti-Plk1 primary Ab was
pre-incubated with recombinant Plk1 enzyme (Invitrogen) before
exposure to the blots. The blots were subsequently stripped and re-
probed with goat anti-b-actin (Santa Cruz Biotechnology, Santa
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Cruz, CA) primary Ab followed by appropriate secondary and
chemiluminescent detection as a loading control. The quantification
of protein was performed by a digital analysis of protein bands (TIFF
images) using UN-SCAN-IT software (Silk Scientific, Orem, UT).
Quantitative real-time RT-PCR
RNA was isolated with Trizol reagent (Invitrogen), treated with
DNAse (Promega, Madison, WI), and first-strand cDNA created with
M-MLV reverse transcriptase (Promega) according to the vendor’s
protocol. Quantitative real-time RT-PCR was performed in triplicate
in 20 ml reactions with SYBR Premix Ex Taq Perfect Real Time
(Takara, Madison, WI) with 50 ng first-strand cDNA and 0.2 mg each
Plk1 forward (50-CCCCTCACAGTCCTCAATAA-30) and reverse (50-
AATAGTCCACCCACTTGCTG-30) primers or 0.2 mg each GAPDH
forward (50-GGGTGTGAACCATGAGAAGT-30) and reverse (50-
GTAGAGGCAGGGATGATGTT-30) primers. Samples were cycled
once at 95 1C for 2minutes, followed by 40 cycles of 95, 58, and
72 1C for 30 seconds each. Relative Plk1 mRNA was calculated using
the DDCT method with GAPDH as an endogenous control.
GW843682X treatment
GW843682X is a reversible and specific ATP competitive Plk1
inhibitor designed by GlaxoSmithKline (Philadelphia, PA) (Lansing
et al., 2007). It was obtained from (Sigma-Aldrich, St Louis, MO),
dissolved in DMSO, and diluted further in cell medium to create a
working stock. The highest volume of DMSO (in cell media) was
used as control. Cells were plated at densities of 5.0 104,
7.5 104, or 5.0 105 in 12-well, 6-well, or 10 cm formats,
respectively. At 24 hours after passaging, the cells were exposed to
increasing doses of GW843682X (5, 10, 15, and 20 mM) or DMSO
control. At 24 or 72 hours after treatment, cells were trypsinized and
collected for further analyses.
Immunoprecipitation and kinase activity assay
After treatment with GW843682X, the cells were trypsinized,
washed with ice-cold PBS, lysed with a non-denaturing lysis buffer
(150mM NaCl, 1.0% NP-40, 0.1% SDS, 50mM Tris pH 8.0, 5mM
EDTA, 5mM NaF) plus phenylmethylsulfonyl fluoride and a protease
inhibitor cocktail (Pierce), and cleared by centrifugation. Lysate
(500mg) was mixed with a 5-mg anti-Plk1 Ab (Upstate) at 4 1C
overnight with rotation. The next day, 50 ml UltraLink Immobilized
Protein A beads (Pierce) were added to the antigen–Ab complex and
incubated for 2 hours at room temperature with rotation. Beads were
recovered by low-speed centrifugation and washed six times with
immunoprecipitation buffer (20mM sodium phosphate pH 7.5,
500mM NaCl, 0.1% SDS, 1% NP-40, 0.02% sodium azide) followed
by one wash with Kinase Buffer (Cell Signaling). The final pellet was
resuspended in 50 ml Kinase Buffer with 50 mM of cold ATP, 10 mg of
dephosphorylated casein (Sigma-Aldrich), and 5mCi of [g-32P]ATP
(Perkin-Elmer, Waltham, MA) and incubated at 30 1C for 30minutes.
To inactivate the reaction, the loading dye was added to each
sample and the mixture was incubated at 95 1C for 5minutes,
centrifuged, and subjected to SDS-PAGE. After appropriate separa-
tion, the gels were dried and analyzed by autoradiography.
Lentiviral production and transduction
For viral creation, HEK 293T cells were passaged to 30–40%
confluency the next day. Cells were transfected using the CaPO4
method. Briefly, 8mg of shRNA plasmid DNA (non-sense shRNA or
Plk1 targeting shRNA; Sigma-Aldrich), 5mg of VSV-G, and 6mg of
D8.2 plasmids were mixed with sterile ddH2O to a final volume of
450ml and mixed with 50ml of 2.5M CaCl2. The DNA mix was
bubbled and 500ml of 2 (HEPES buffered saline) (pH 7.05) was
added dropwise. The transfection mixture was added to its respective
plates and incubated overnight. After 24hours, the transfection media
were removed and fresh media were added. After an additional 24
and 48hours, cell media containing shRNA lentivirus were collected
and filtered for use.
For target cell transduction, melanoma cells were passaged to
40% confluency the next day. Viral media were added to cells with
8mgml1 of polybrene four times over 2 days. After 72 hours of
transduction, the viral media were removed and cells were collected
for further experiments. Owing to the phenotypes caused by shPlk1
infection and a rapid decrease in cell number, selection for
transfected cells was not possible; however, the efficacy of each
batch of Plk1 shRNA particles was routinely checked through
immunoblot analysis for Plk1 expression before further experiments.
Trypan blue exclusion assay
At 72 hours post GW843682X treatment or shRNA transduction,
cells were trypsinized and collected in a 1.5-ml tube, pelleted by
centrifugation, and resuspended in 120ml of PBS. A 10-ml aliquot of
cell suspension was removed and an equivalent 10ml of Trypan blue
was added to the cells. The cells were then counted for viability
(viable¼ unstained, non-viable¼ stained) and total cell growth.
MTT assay
For MTT assay, 2 103 cells were plated in a 96-well plate. At
24hours post plating, cells were treated with GW843682X or shRNA
as described previously. At 72hours post treatment, 4ml of MTT
reagent (5mgml1 in cell media) was added to each well and
incubated for 2hours. MTT reagent was removed by aspiration and
replaced with formazan crystals dissolved in DMSO. Absorbance was
read at 540–690nm. Data were represented as percentage reduction in
metabolic activity, normalized to DMSO or non-sense shRNA control.
Colony formation
Cells were plated at a density of 3.0 103 in six-well plates. At
24 hours later, the cells were treated with GW843682X or shRNA as
described above. GW843682X-treated cells were subsequently
retreated every 3 days for 2 weeks. For the cells treated with
shRNA, media were removed and replaced with normal cell media
every 3 days, with no further selection or treatment. The cells were
then stained after the 2-week treatment regimen with 0.1% crystal
violet diluted in water and methanol (2:2:1 ratio), washed with PBS,
and air-dried. The number of colonies per well was counted and the
pictures were obtained using a digital camera.
Cell-cycle analysis
After treatments, the cells were trypsinized, washed with PBS, and
fixed in ice-cold 100% ethanol. Cells were then washed with PBS
and stained with PI (Invitrogen) and analyzed on an FACScan
benchtop cytometer at the University of Wisconsin Paul P. Carbone
Comprehensive Cancer Center (UWCCC) Flow cytometry facility
(Madison, WI). Cell-cycle distribution was analyzed using CellQuest
software (BD Biosciences, San Jose, CA).
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Immunofluorescence studies
For immunofluorescence staining, the cells were plated and grown
on BD Falcon CultureSlides (BD Biosciences) and treated with
shPlk1 or GW843682X (10 mM) as described previously. The cells
were fixed with 100% methanol and permeabilized with 0.5%
Triton-X 100 in PBS and then blocked for 1 hour at room temperature
in 10% normal goat serum in PBS. After blocking, biotin-conjugated
mouse anti-a-tubulin Ab (Molecular Probes, Carlsbad, CA) (1:100 in
blocking buffer) was added and allowed to incubate for 2 hours at
room temperature. Primary Ab was removed and streptavidin
Alexa Fluor 568 (Molecular Probes) (1:200 in blocking buffer) was
added and incubated for 1 hour at room temperature in the dark.
40,6-Diamidino-2-phenylindole, dihydrochloride (DAPI) (Pierce)
(1mgml1) counterstain was used for nuclear staining. The cells were
mounted with ProLong Antifade kit (Molecular Probes) as per the
vendor’s protocol and examined under Bio-Rad Radiance 2100 MP
Rainbow Confocal/Multiphoton System (Bio-Rad, Hercules, CA). For
mitotic error quantitation, at least 100 mitotic cells were scored as
either undergoing normal mitosis or possessing one of multiple errors,
including monopolar, multipolar, improper tubulin size or attachment,
improper DNA condensation or separation, or errors in cytokinesis.
Annexin V analysis
After treatments, cells were trypsinized, collected, and washed in
Dulbecco’s PBS (DPBS). The cells were then resuspended in 100ml
binding buffer (0.1M Hepes (4-(2-hydroxyethyl)-1-piperazineethane-
sulfonic acid), pH 7.4; 1.4 M NaCl; 25mM CaCl2) with anti-Annexin
V Ab and PI (BD Biosciences) as per the vendor’s suggestions. The
cells were then analyzed on an FACScan benchtop cytometer at the
UWCCC Flow cytometry facility, and further analysis was carried
out using CellQuest software (BD Biosciences).
Statistics
All results, unless otherwise noted, are expressed as the mean±SD.
Statistical analyses were carried out by two-tailed Student’s t-test.
Data for immunohistochemical analysis were compared using a two-
tailed Fisher’s exact test. For all analysis, a P-value o0.01 was
considered statistically significant, unless otherwise noted.
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